Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Saved in:
| Title: | Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia. |
|---|---|
| Authors: | Vistisen D; Steno Diabetes Center Copenhagen, Copenhagen, Denmark.; Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Carstensen B; Steno Diabetes Center Copenhagen, Copenhagen, Denmark., Elisabetta P; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Lanzinger S; Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany.; German Centre for Diabetes Research (DZD), Munich-Neuherberg, Germany., Tan EC; Department of Health Service Administration, China Medical University, Taichung, Taiwan., Yabe D; Yutaka Seino Distinguished Centre for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan.; Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.; Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan.; Preemptive Food Research Centre, Gifu University Institute for Advanced Study, Gifu, Japan., Kim DJ; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea., Sheu WH; Insititute of Molecular and Genomic Medicine, National Health Research Institutes, Taipei City, Taiwan., Melzer-Cohen C; Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel-Aviv, Israel., Holl RW; Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany., Núñez J; Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain., Ha KH; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea., Halvorsen S; Department of Cardiology, Oslo University Hospital Ullevål, University of Oslo, Oslo, Norway., Langslet G; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Lipid Clinic, Oslo University Hospital, Oslo, Norway., Karasik A; Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel-Aviv, Israel., Nyström T; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden., Niskanen L; Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti, Finland.; University of Eastern Finland, Kuopio, Finland., Guleria S; IQVIA, Goteborg, Sweden., Klement R; IQVIA, Tartu, Estonia., Carrasco M; Boehringer Ingelheim Pharmaceuticals, Inc., Barcelona, Spain., Foersch J; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Shay C; Boehringer Ingelheim Pharmaceuticals USA, 00 Ridgebury Road, Ridgefield, CT, 06877, USA. christina.shay@boehringer-ingelheim.com., Koeneman L; Lilly Deutschland GmbH, Bad Homburg, Germany., Hoti F; IQVIA, Espoo, Finland., Farsani SF; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Khunti K; Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK., Zaccardi F; Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK., Subramanian A; Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Nirantharakumar K; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.; Midlands Health Data Research UK, Birmingham, UK.; DEMAND Hub, University of Birmingham, Birmingham, UK. |
| Corporate Authors: | EMPRISE EU, East Asia Study Group |
| Source: | Cardiovascular diabetology [Cardiovasc Diabetol] 2023 Aug 31; Vol. 22 (1), pp. 233. Date of Electronic Publication: 2023 Aug 31. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1475-2840 |
|---|---|
| DOI: | 10.1186/s12933-023-01963-9 |
